



Revenio Group Corporation: Interim Report January 1 - September 30, 2013 - REVENIO HEALTH TECH CONTINUES ON A GROWTH TRACK, POSITIVE DEVELOPMENT EXPECTED ALSO FOR THE REST OF THE YEAR

Revenio Group Corporation Stock exchange release October 22, 2013 at 9.00 a.m.

Revenio Group Corporation's Interim Report January 1 - September 30, 2013 - REVENIO HEALTH TECH CONTINUES ON A GROWTH TRACK, POSITIVE DEVELOPMENT EXPECTED ALSO FOR THE REST OF THE YEAR

Highlights for July-September 2013:

- * Revenio Health Tech segment clearly increased its sales and profits. The Health Tech segment grew particularly strongly in United States, Japan, Australia, Canada and Denmark.
- * The Software and Contact Center businesses were the most successful businesses in the Revenio Technology and Service segment, Rigid Inflatable Boat operations also experienced growth
- * Positive development is expected to continue for the rest of the year
- * The Board decided on a repayment of capital of EUR 0.12 per share, according to the authorization it had received on March 21, 2013.
- * The Group organized a capital market day on August 28, 2013.
- * The Group's financial guidance for 2013 remains unchanged: In continuing operations, consolidated net sales and operating profit excluding non-recurring items are expected to see year-on-year growth.

Highlights for January-September:

- * Sales and operating profit of the Revenio Health Tech segment showed strong growth.
- * Revenio Technology and Services segment saw a year-on-year performance improvement measured by both net sales and operating profit.

Group key figures:

7-9/2013

- * Net sales EUR 6.7 (6.1) million, an increase of 10.3 percent.
- * Operating profit EUR 1.5 (1.4) million, or 21.8 (22.5) percent of net sales.
- * Revenio Health Tech segment EUR 3.0 (2.6) million, an increase of 15.1 percent.
- * The operating profit of Revenio Health Tech was EUR 1.2 million (1.0 million), representing 38.9 (38.6) %, of net sales, change EUR 0.2 million, an increase of 13.2 %.
- * Net sales of the Revenio Technology and Services segment EUR 3.7 million (EUR 3.4 million), an increase of 6.6 percent.
- * The operating profit of Revenio Technology and Services was EUR 0.5 million (EUR 0.5 million), representing 13.3 (13.3) percent of net sales, a change of EUR -0.0 million, a decrease of 5.5%.
- * Result for discontinued operations EUR 0.0 million (EUR -0.2 million), no impact on the third-quarter result.
- * Diluted and undiluted earnings per share came to EUR 0.14 (EUR -0.03).

1-9/2013

- * Net sales EUR 20.7 (17.7) million, an increase of 17.0 percent.
- * Operating profit EUR 4.1 (3.5) million, or 19.6 (19.9) percent of net sales.
- * Revenio Health Tech segment EUR 9.4 (7.8) million, an increase of 19.9 percent.

- * The operating profit of Revenio Health Tech was EUR 3.6 million (3.3 million), representing 38.6 (41.7) %, of net sales, change EUR 0.3 million, an increase of 11.1%.
- * Net sales of the Revenio Technology and Services segment EUR 11.3 million (EUR 9.9 million), an increase of 14.6 percent
- * The operating profit of Revenio Technology and Services was EUR 1.1 million (EUR 1.0 million), representing 9.3 (10.0) percent of net sales, change EUR 0.1 million, an increase of 6.9 %.
- * Result for discontinued operations EUR 0.0 million (EUR -2.2 million), no impact on the review period
- * Pre-tax profit, continuing operations, EUR 4.0 (3.3) million.
- * Undiluted earnings per share, continuing operations EUR 0.38 (0.32).
- * Diluted earnings per share, continuing operations EUR 0.38 (0.32).
- * Diluted and undiluted earnings per share, discontinuing operations EUR 0.00 (-0.28).
- * Diluted and undiluted earnings per share, continuing and discontinuing operations EUR 0.38 (0.04).
- * Cash flow from continuing operations EUR 3.1 (1.8) million.

Olli-Pekka Salovaara, President & CEO:

"The Revenio Group's third quarter continued positively. The business operation development in Health Tech segment grew strongly, as per my expectations. Technology and Services had the best quarter of the year thus far.

As stated in our strategy, our focus this year will be on creating growth opportunities in the Health Tech segment while increasing the segment's operating profit. The early year's growth of sales and profitability shows that we are advancing according to our strategy.

Our Health Tech segment experienced a strong growth of sales and profits during the review period. The sales were particularly strong in the United States, Japan, Australia, Canada, Denmark and Norway. In Russia, the sales have continued to grow as planned, and the Southern European sales revival seems to have strengthened.

The sales of disposable probes for tonometers continued to grow as a result of the continued and increasing use of devices already sold. The expanding stock of sold equipment will open up the markets for future replacement devices.

In line with our strategy, the Technology and Services segment will focus on securing profitable growth. The strongest developing sales of the segment were in Contact Center business ja Software business. Rigid Inflatable Boat operations also experienced considerable growth.

In August, we organized a capital market day, going through the strategic focal areas and growth drivers of the Revenio group. We will continue strive to develop our visibility in the domestic and international fields of investors."

JULY-SEPTEMBER 2013 COMMENTS:

REVENIO HEALTH TECH

The aim of Icare Finland Oy, which forms the Revenio Health Tech segment, is achieving world market lead in intraocular pressure screening and measurement.

The segment's current main markets are in North America, Europe, Russia and selected Asian countries, such as Japan and India. Market areas that we still have not tapped into and that offer considerable potential include South America and China.

The sales of Revenio Health Tech segment in July-September 2013 were EUR 3.0 (2.6) million, growing by 15.1 percent.

The market situation remained good throughout the review period. The sales grew in all of the main market areas of the segment. In addition to Finland, United States, Japan, Canada and Australia, the sales perked up clearly in Denmark and Norway.

A version of Icare One, designed for intraocular pressure self-measurement, has been prepared for the start of a FDA licensing process in the United States with product changes actualized during the review period. The product and the license application plan have been presented to the FDA, and according to the received feedback, the machine will be ready for usability tests and clinical tests in the United States. After those tests, according to our estimations, we can apply for the license in early 2014.

During the review period, the Icare Finland Oy organization has been strengthened by the new key staff recruitments for sales, approval processes and

product development. The well-targeted recruitments are aimed at strengthening the company's market position, particularly in the developing markets, and retaining the competitive edge in product development.

The sales of disposable eye pressure meter probes grew 26% during the review period, which shows the active use of the sold equipment. The probe sales represent approximately a fifth of the total segment sales.

REVENIO TECHNOLOGY AND SERVICES

On December 1, 2012, the Revenio Technology and Services segment was formed from four Group businesses and companies, and some functions of the Group's parent company. The businesses included in this segment are the Contact Center business, Rigid Inflatable Boats business, Information Displays business, and Software business.

In line with its strategy, Revenio's Technology and Services segment is focusing on organic growth, efficiency, and profitability improvement.

In July-September, the segment recorded net sales of EUR 3.7 (3.4) million; an increase of 6.6 percent compared to the same period last year.

The Contact Center business showed a clear growth of sales and profits during the review period. This growth has been created by the development of inbound sales and success of outbound campaigns and projects of the company's key area of expertise. The earlier investments in the production technology of the field have improved business productivity and service fluency.

In the Rigid Inflatable Boat business, the review period production consisted of several highly demanding boat projects. The sales and profits increased. Customers are demanding faster and faster boats, and the need for customer-based tailoring is considerable. This presents production efficiency and sustainability development challenges for the manufacture of small series.

In the Information Display business, demand is primarily affected by investment programs that large oil company customers use to actualize their distributor network revamps. During the current year, there have been no important revamp programs, but demand has been formed by customer replenishment programs. The sales and profits were lower than during the record-breaking last year. During the review period, we received an important order of parking management system for Kaari, a commerce center in Helsinki.

In our software business, during the review period, we mainly focused on the expansion of our current customers' systems and small developments relating to the maintenance of the currently existing systems of our customers. Our sales decreased somewhat from the last year, but profitability continued to be good. Considering the current economic situation, our market situation is challenging, but our customers still evaluate the logistics and potentially productivity-improving projects in these conditions, forming the market potential of the Software business.

Net sales and segment's margin excluding non-recurring items were as follows:

	Net Sales		Net Sales		Segment profit margin		Segment profit margin	
	1-9/2013	1-9/2012	1-9/2013	1-9/2012	1-9/2013	1-9/2012	1-9/2013	1-9/2012
	MEUR	share-%	MEUR	share-%	MEUR	%	MEUR	%
Revenio Health Tech	9.4	45	7.8	44	3.6	39	3.3	42
Revenio Technology and Services	11.3	55	9.9	56	1.1	9	1.0	10
Total	20.7	100	17.7	100	4.7	23	4.3	24
Parent company expenses					-0.6		-0.7	

Operating
Profit, Group
Total

4.1 20 3.5 20

The net sales, margin, and profit, by segment and quarter , excluding non-recurring items, were as follows:

MEUR	Q3/13	Q2/13	Q1/13	Q4/12	Q3/12	Q2/12	Q1/12
Net sales:							
Revenio Health Tech	3.0	3.2	3.1	3.2	2.6	2.6	2.6
Revenio Technology and Services	3.7	3.7	4.0	4.5	3.4	3.2	3.2
Total	6.7	6.9	7.1	7.7	6.1	5.8	5.8
Segment profit margin:							
Revenio Health Tech	1.2	1.3	1.1	1.2	1.0	1.0	1.1
Revenio Technology and Services	0.5	0.4	0.2	0.5	0.5	0.2	0.2
Total	1.7	1.7	1.3	1.7	1.6	1.3	1.3
Parent co. expenses	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2
Operating profit	1.5	1.5	1.2	1.4	1.4	1.0	1.2
Operating profit-%	22	20	16	18	22	17	20

PERSONNEL

During the review period, the number of personnel employed by the Group in continuing operations averaged 221 (198). At the end of the period, the number of employees stood at 239 (215).

Average no. of employees by segments:

	30 Sept 2013	30 Sept 2012	Change
Revenio Health Tech	16	13	3
Revenio Technology and Services	201	181	20
Parent Company	4	4	0
Group Total	221	198	23

During the review period, the total paid wages and fees have been EUR 5.6 (5.0) million.

NET SALES AND FINANCIAL PERFORMANCE

Consolidated net sales from the Revenio Group's continuing operations for the period January 1-September 30, 2013, totaled EUR 20.7 (17.7) million, This represented a net sales growth of 17.0 percent. Earnings before interest, taxes,

depreciation and amortization (EBITDA) from continuing operations amounted to EUR 4.6 (4.0) million, or 22.4 (22.9) percent of net sales. The sales for continuing operations were EUR 4.1 (3.5) million, representing 19.6% (19.9) of the net sales. Profit before taxes for continuing operations totaled EUR 4.0 (3.3) million, or 19.2 (18.7) percent of net sales. The net result for continuing operations was EUR 3.0 million (EUR 2.5 million), or 14.5 (14.1) percent of net sales. Net result for discontinued operations totaled EUR 0.0 (-2.2) million. Net profit for the period totaled EUR 3.0 million (EUR 0.3 million).

Both undiluted earnings per share for continuing operations and dilution-adjusted earnings per share came to EUR 0.38 (0.32). For discontinued operations, the undiluted and diluted earnings per share were EUR 0.00 (-0.28).

Dilution-adjusted earnings per share for continuing and discontinued operations during the period were EUR 0.38 (0.04). Equity per share was EUR 2.03 (1.99).

During the review period, the consolidated net sales of continuing operations saw a year-on-year increase of 17.0 percent. The Revenio Health Tech segment and the Revenio Technology and Services segment's Contact Center and Rigid Inflatable Boats businesses accounted for the strongest net sales growth.

The Revenio Health Tech segment increased its operating profit compared to the same period a year earlier. At this development phase of the business, planned investments are made to the conditions of future growth by strengthening sales and product development, among other things. Regardless, the segment's operating profit grew to EUR 3.6 (3.3) million. In the Technology and Services segment, operating profit rose to EUR 1.1 (1.0) million.

On December 18, 2012, the Group decided to divest Done Logistics Oy. The company has since been categorized as 'discontinued operations' in consolidated reporting. This change in reporting also applies to reference figures. The parts of business that are related to the discontinuation were sold on February 7, 2013. The business of discontinued operations consists of finishing the Norwegian projects. This is estimated to happen during 2014.

BALANCE SHEET, FINANCIAL POSITION AND INVESTMENTS

The consolidated balance sheet total stood at EUR 22.2 (24.4) million on September 30, 2013. Shareholders' equity came to EUR 15.9 (15.3) million. At the end of the review period, interest-bearing net liabilities amounted to EUR -1.7 (0.3) million and gearing stood at -10.4 (2.1) percent. The consolidated equity ratio was 73.4 (63.8) percent. The Group's liquid assets amounted to EUR 3.2 (3.8) million at the end of the review period. Thanks to favorable trends in operations, the Group's financial position remained stable throughout the review period. No financing was raised through borrowed capital during the review period. Revenio's financial position was also bolstered by funds received from shares subscribed to via options, a total of EUR 0.8 million. Cash flow from continuing operations totaled EUR 3.1 million. The Group's purchases of PPE and intangible assets totaled EUR 0.5 (0.4) million. These investments were concentrated on product development and, to a lesser degree, information technology and software.

SHARES, SHARE CAPITAL AND MANAGEMENT HOLDINGS

On September 30, 2013, the Revenio Group Corporation's fully paid-up share capital registered with the Trade Register was EUR 5,314,918.67 and the number of shares totaled 7,838,909. During the review period, the number of shares increased by 145,936 following subscriptions made on the basis of the 2007 stock option scheme. Additionally, after the review period, the amount of stock increased by 4,125 shares. In all, during the current accounting period, Series 2007A option rights were used to subscribe for 100,624 shares, 2007B option rights to subscribe for 16,212 shares and 2007C options rights to subscribe for 33,225 shares. The subscription period for 2007A options ended on May 1, 2013. The outstanding 2007B (696,000 option rights) and 2007C (627,750 option rights) options can be used to subscribe for a total of 132,375 shares until the close of the subscription period on November 1, 2014 (2007B) and May 1, 2016 (2007C). The company has one class of share, and all shares confer the same voting rights and an equal right to dividends and the company's funds. On September 30, 2013, the President & CEO and members of the Board of Directors held 6.8 percent of the company's shares (536,149 shares) and 0.0 percent of the option rights.

CHANGES IN SHAREHOLDING

During the review period of May 10, 2013, it was announced that the ownership of Joensuun Kauppa ja Kone Oy in Revenio Group Oyj shares and votes was now over one in twenty (1/20). Joensuun Kauppa ja Kone Oy's share in Revenio Group Oyj shares and votes was, at the moment of announcing, 5.02 percent, meaning 389,626 shares.

OPTION RIGHTS

On the basis of the share issue authorization approved by the Annual General Meeting of April 3, 2007, the Board of Revenio Group Corporation decided, on November 23, 2007, on a new corporate option scheme comprising a maximum of 3,684,365 option rights. Ten option rights entitle the holder to subscribe for one (1) Revenio Group Corporation share. According to external option rights, the amount of shares that could still be marked up on September 30, 2013 was a maximum of 1.9 percent of the company's shares and votes when the new shares have been registered using option rights. New shares subscribed for via the option program entitle the holder to a dividend from the subscription year onwards.

The option rights have been divided into three series: Series A (1,684,365), B (1,000,000) and C (1,000,000). The subscription periods are as follows: Series A, May 1, 2009-May 1, 2013, Series B, November 1, 2010-November 1, 2014, and Series C, May 1, 2012-May 1, 2016. The share subscription price will be the trade-weighted average price during the period April 1-30, 2009 multiplied by ten (EUR 2.35, Series B) and November 1-30, 2010 multiplied by ten (EUR 2.29, Series C).

No new options were issued to the personnel during the review period.

TRADING ON NASDAQ OMX HELSINKI

During the period January 1 - September 30, 2013, the Revenio Group Corporation's share turnover on the NASDAQ OMX Helsinki exchange totaled EUR 18.1 (8.4) million, representing 2.4 (2.0) million shares or 31.0 (25.9) percent of all shares outstanding after the reverse share split of March 27, 2013.

The highest trading price was EUR 11.58 (5.00) and the lowest EUR 4.10 (3.30). At the end of the review period, the closing price was EUR 10.58 (3.80), and the average share price EUR 7.44 (4.20). The Revenio Group Corporation's market value stood at EUR 82.9 (29.2) million on September 30, 2013. These figures take into account the effects of the reverse share split.

RISK MANAGEMENT

The Group's major business risks are presented in its financial statement bulletin of February 8, 2013. No changes in these risks have occurred since the bulletin's release.

ANNUAL GENERAL MEETING AND BOARD AUTHORIZATIONS IN EFFECT

The Annual General Meeting held on March 21, 2013 approved the company's financial statements and discharged the President & CEO and the members of the Board of Directors from liability for the financial year January 1-December 31, 2012.

The AGM re-elected Pekka Tammela and Rolf Fryckman as members of the Board, and elected Ari Kohonen as a new member. The AGM decided that the Chairman of the Board should be paid a fee of EUR 36,000 per annum and other Board members EUR 18,000 per annum. For the Board members, 60 percent of the fee is paid as monetary compensation and 40 percent in company shares.

The AGM re-elected PricewaterhouseCoopers Oy, Authorized Public Accountants, as the company's auditors with Juha Tuomala, Authorized Public Accountant, as principal auditor.

The AGM accepted the Board's proposal on profit distribution, according to which the profit for the financial period, EUR 1,545,444.10, will be added to retained earnings, and a dividend of EUR 0.02 per share will be paid to a total of EUR 1,551,862.94.

The AGM authorized the Board of Directors to distribute funds to shareholders, at its own discretion, as a capital repayment from the invested unrestricted equity reserve. The maximum amount of equity distributed to shareholders on the basis of the authorization would be EUR 1,000,000.00. The authorization will be valid until the beginning of the next Annual General Meeting.

The AGM authorized the Board of Directors to decide on the acquisition of a

maximum of 777,107 of the company's own shares, either in one or several installments, using the company's unrestricted equity, in which case any buyback will reduce the amount of distributable earnings.

The AGM canceled the Board of Directors' valid unexercised share-issue authorizations, and authorized the Board to decide to issue a maximum of 3,000,000 shares or to grant special rights (including stock options) entitling to shares, as referred to in Section 1 of Chapter 10 of the Limited Liability Companies Act, in one or several installments. This authorization was granted for use in financing and implementing any prospective corporate acquisitions or other transactions, for implementing the company's share-based incentive plans, or for other purposes determined by the Board. The Board has the right to decide on all terms and conditions governing said share issue and the granting of special rights, including the subscribers or grantees of the special rights, and the consideration payable. The Board's authorization includes the right to waive shareholders' preemptive subscription rights and covers the issue of new shares and the transfer of any shares that may be held by the company. This authorization is valid until April 30, 2014.

BOARD OF DIRECTORS AND AUDITORS

As of March 21, 2013, the Revenio Group Corporation's Board of Directors consists of: Pekka Tammela, M.Sc. (Econ.), Authorized Public Accountant, partner in P J Maa Partners Oy (Chairman); Rolf Fryckman, optician, Chairman of the Board of Eyemaker's Finland Oy; and - a new member as of March 21, 2013 - Ari Kohonen, M.Sc. (Eng.), M.Sc. (Econ.). Kohonen acts as the Chairman of the Board of Gerako Oy.

PricewaterhouseCoopers Oy, Authorized Public Accountants, serves as the company's auditor, with Juha Tuomala, Authorized Public Accountant, as principal auditor.

MAJOR EVENTS AFTER THE REVIEW PERIOD

There have been no major events since the end of the review period.

OUTLOOK FOR 2013

Our estimate of the prospects for 2013 continues to hold: It is estimated that the sales and profits of the Group's ongoing operations grows from 2012, not considering one-time batches.

STATEMENT OF ACCOUNTING POLICIES

The recognition and valuation principles underlying the financial information presented in this Interim Report comply with the principles of the International Financial Reporting Standards (IFRS). The report does not comply with all the requirements of IAS 34, Interim Financial Reporting. The figures are unaudited.

GROUP KEY FIGURES AND RATIOS (MEUR)	1-9/2013	1-9/2012	1-12/2012
Net sales, continuing operations	20.7	17.7	25.4
Ebitda, continuing operations	4.6	4.0	5.7
Ebitda-%, continuing operations	22.4	22.9	22.5
Operating profit, continuing operations	4.1	3.5	4.9
Operating profit-%, continuing operations	19.6	19.9	19.4
Pre-tax profit, continuing operations	4.0	3.3	4.7
Pre-tax profit-%, continuing operations	19.2	18.7	18.5
Net profit from discontinued operations	0.0	-2.2	-3.8

Net profit, continuing operations	3.0	2.5	3.5
Net profit-%, continuing operations	14.5	17.6	13.8
Gross capital expenditure	0.5	0.4	0.3
Gross capital expenditure-%	2.5	2.2	1.1
R&D costs	0.2	0.2	0.4
R&D costs-% from net sales	0.9	1.3	1.4
Gearing-%	-10.4	2.1	-12.2
Equity ratio-%	73.4	63.8	62.2
Return on investment-% (ROI)	27.3	20.9	0.4
Return on equity-% (ROE)	26.2	26.2	-1.8
Undiluted earnings per share, EUR, continuing operations	0.38	0.32	0.59
Diluted Earnings per share, EUR, continuing operations	0.38	0.32	0.59
Undiluted earnings per share, EUR, discontinued operations	0.00	-0.28	-0.63
Diluted Earnings per share, EUR, discontinued operations	0.00	-0.28	-0.63
Equity per share, EUR	2.03	1.99	1.91
Average no. of employees, continuing operations	221	198	198
Cash flow from operating activities	3.1	1.8	4.8
Cash flow from discontinued operations	-0.9	-2.6	-4.0
Cash flow from investing activities	-0.5	-0.1	-0.1
Net cash used in financing activities	-3.3	0.8	-0.2
Total cash flow	-1.8	-0.6	0.5

CONSOLIDATED COMPREHENSIVE 1-9/2013 1-9/2012 1-12/2012

INCOME STATEMENT (MEUR)

NET SALES	20.7	17.7	25.4
Other operating income	0.0	0.1	0.1
Materials and services	-5.8	-4.4	-6.9
Employee benefits	-6.8	-6.1	-8.4
Depreciation/amortization	-0.6	-0.5	-0.8
Other operating expenses	-3.5	-3.3	-4.5
OPERATING PROFIT, CONTINUING OPERATIONS	4.1	3.5	4.9
Share of associates' results	0.0	0.0	0.0

Financial expenses (net)	-0.1	-0.2	-0.2
PRE-TAX PROFIT, CONTINUING OPERATIONS	4.0	3.3	4.7
Income tax expense	-1.0	-0.8	-1.1
Net profit from continuing operations	3.0	2.5	3.5
Net profit from discontinued operations	0.0	-2.2	-3.8
NET PROFIT	3.0	0.3	-0.3
Other comprehensive income items	0.0	0.0	0.0
Income tax expense for comprehensive income	0.0	0.0	0.0
Other comprehensive income items after taxes	0.0	0.0	0.0
TOTAL COMPREHENSIVE INCOME	3.0	0.3	-0.3
Net profit attributable to:			
Parent company shareholders	3.0	0.3	-0.3
Total comprehensive income attributable to:			
Parent company shareholders	3.0	0.3	-0.3
Earnings per share, undiluted, EUR, continuing operations	0.38	0.32	0.59
Earnings per share, diluted, EUR, continuing operations	0.38	0.32	0.59
Earnings per share, undiluted, EUR, discontinued operations	0.00	-0.28	-0.63
Earnings per share, diluted, EUR, discontinued operations	0.00	-0.28	-0.63

CONSOLIDATED COMPREHENSIVE

INCOME STATEMENT (MEUR)	7-9/2013	7-9/2012
NET SALES	6.7	6.1
Other operating income	0.0	0.0
Materials and services	-1.9	-1.6
Employee benefits	-2.1	-1.9
Depreciation/amortization	-0.2	-0.2
Other operating expenses	-1.1	-1.1
OPERATING PROFIT, CONTINUING OPERATIONS	1.5	1.4
Share of associates' results	0.0	0.0
Financial expenses (net)	-0.1	0.0
PRE-TAX PROFIT, CONTINUING OPERATIONS	1.4	1.4

Income tax expense	-0.3	-0.3
Net profit from continuing operations	1.1	1.1
Net profit from discontinued operations	0.0	-0.2
NET PROFIT	1.1	0.9
Other comprehensive income items	0.0	0.0
Income tax expense for comprehensive income	0.0	0.0
Other comprehensive income items		
after taxes	0.0	0.0
TOTAL COMPREHENSIVE INCOME	1.1	0.9
Net profit attributable to:		
Parent company shareholders	1.1	0.9
Total comprehensive income attributable to:		
Parent company shareholders	1.1	0.9

CONSOLIDATED BALANCE SHEET (MEUR)

	30 Sept 2013	30 Sept 2012	31 Dec 2012
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	1.5	1.6	1.6
Goodwill	8.1	8.1	8.1
Intangible assets	0.7	0.7	0.6
Shares in associates	0.0	0.0	0.0
Deferred tax assets	0.5	1.5	1.6
TOTAL NON-CURRENT ASSETS	10.9	12.0	12.0
CURRENT ASSETS			
Inventories	1.6	1.4	1.3
Trade and other receivables	5.0	4.7	4.8
Cash and cash equivalents	3.2	3.8	5.0
TOTAL CURRENT ASSETS	9.8	10.0	11.2
Non-current assets held			
for sale	1.6	2.4	1.8
TOTAL ASSETS	22.2	24.4	25.0
LIABILITIES AND SHAREHOLDERS' EQUITY			
SHAREHOLDERS' EQUITY			

Share capital	5.3	5.3	5.3
Share premium	2.4	2.4	2.4
Fair value reserve	0.3	0.3	0.3
Invested unrestricted capital reserve	6.9	7.3	7.1
Retained earnings/loss	1.0	-0.1	-0.4
TOTAL EQUITY. attributable to holders			
of parent company equity	15.9	15.3	14.7
TOTAL SHAREHOLDERS' EQUITY	15.9	15.3	14.7
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred tax liabilities	0.2	0.2	0.2
Provisions	0.1	0.1	0.1
Financial liabilities	1.0	2.0	1.4
TOTAL LONG-TERM LIABILITIES	1.3	2.3	1.7
CURRENT LIABILITIES			
Advance payments	0.5	0.4	1.4
Trade and other payables	3.2	2.9	3.3
Financial liabilities	0.6	2.1	1.8
TOTAL SHORT-TERM LIABILITIES	4.3	5.4	6.5
Long-term liabilities held for sale	0.7	1.4	2.1
TOTAL LIABILITIES	6.3	9.1	10.3
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	22.2	24.4	25.0

CONSOLIDATED STATEMENT OF CHANGE IN EQUITY (MEUR)

	Share capital	Share Premium	Other Reserves	Retained Earnings	Total Equity
Balance 1 Jan 2013	5.3	2.4	7.4	-0.4	14.7
Dividend distribution	0.0	0.0	0.0	-1.6	-1.6
Option rights utilized	0.0	0.0	0.7	0.0	0.7
Repayment of capital	0.0	0.0	-0.9	0.0	-0.9

Net profit	0.0	0.0	0.0	3.0	3.0
Balance 30 June 2013	5.3	2.4	7.2	1.0	15.9
	Share	Share	Other	Retained	Total
	capital	Premium	Reserves	Earnings	Equity
Balance 1 Jan 2012	5.3	2.4	7.3	1.3	16.4
Dividend distribution	0.0	0.0	0.0	-1.5	-1.5
Options expense					
adjustment	0.0	0.0	0.0	0.1	0.1
Net profit	0.0	0.0	0.0	0.3	0.3
Balance 30 June 2012	5.3	2.4	7.3	0.2	15.3

CONSOLIDATED CASH FLOW STATEMENT (MEUR)	1-9/2013	1-9/2012	1-12/2012
Net profit	3.0	0.2	-0.3
Adjustments to net profit	1.7	1.0	5,2
Change in working capital	-1.6	0.5	-0.1
Interest paid	-0.0	-0.0	-0.1
Interest received	0.0	0.0	0.0
CASH FLOW FROM OPERATING ACTIVITIES	3.1	1.7	4.8
Cash flow from discontinued operations	-0.9	-3.1	-4.0
Sales of subsidiaries			
and associates' shares (net)	0.0	0.2	0.2
Purchase of PPE	-0.2	-0.2	-0.3
Purchase of Intangible assets	-0.3	-0.1	0.0
NET CASH USED IN INVESTING ACTIVITIES	-0.5	-0.1	-0.1
Used options rights	0.8	0.0	0.0
Paid dividends and repayments of capital	-2.5	-1.5	-1.5
Repayments of long-term borrowings	-1.5	-1.3	-1.7
Long-term loans received	0.0	3.8	3.2
Finance lease principal payment	-0.1	-0.1	-0.1
Loans for associated companies granted	-0.0	-0.0	-0.1
NET CASH USED IN FINANCING ACTIVITIES	-3.3	0.8	-0.2
Net change in cash and equivalents	-1.8	-0.6	0.5
Cash and equivalents. period-start	5.0	4.4	4.4
Cash and equivalents. period-end	3.2	3.8	5.0

NET SALES AND OPERATING PROFIT BY QUARTER
(MEUR)

	Q3/2013	Q2/2013	Q1/2013	Q4/2012	Q3/2012	Q2/2012	Q1/2012
Net sales	6.7	6.9	7.1	7.7	6.1	5.8	5.8
Oper. Profit	1.5	1.5	1.2	1.4	1.4	1.0	1.2
Oper. profit.-%	22	20	16	18	23	17	20

MAIN SHAREHOLDERS 30 Sept. 2013

	No. of shares	%
1. Merivirta Jyri	1,000,000	12.8
2. Eyemakers' Finland Oy	500,000	6.4
3. Joensuun Kauppa ja Kone Oy	431,763	5.5
4. Sijoitusrahasto Evli Suomi Osake	371,076	4.7
5. Keskinäinen Eläkevakuutusyhtiö Etera	350,000	4.5
6. Gerako Oy	340,000	4.3
7. Alpisalo Mia	288,669	3.7
8. Salovaara Olli-Pekka	151,330	1.9
9. Kirkon Keskusrahasto	104,867	1.3
10. Keskinäinen vakuutusyhtiö Fennia	89,822	1.2

Revenio Group Corporation
Board of Directors

For additional information:
President&CEO Olli-Pekka Salovaara,
+358(0)40567 5520
olli-pekka.salovaara@revenio.fi
<http://www.revenio.fi>

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy. The widely patented Icare product family is the current cornerstone of the Group's success. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers.

The Revenio Group also includes other business operations, which are grouped under the Technology and Services segment. This segment's operations have a shared global market and represent the cutting edge of technology products and services in their industry. These businesses are extremely profitable in their

industries and generate positive cash flow.

In 2012, the Revenio Group's net sales totaled EUR 25.4 million, with its operating margin standing at 19.4 percent. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.

[HUG#1736983]

This news release was distributed by GlobeNewswire, www.globenewswire.com – a Nasdaq company